Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
CORV was delisted on the 26th of May, 2020.
25 hedge funds and large institutions have $38.3M invested in Correvio Pharma Corp. Ordinary Shares (Canada) in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
40% more capital invested
Capital invested by funds: $27.3M → $38.3M (+$11M)
7% less funds holding
Funds holding: 27 → 25 (-2)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$72.5K |
| 2 |
Renaissance Technologies
New York
|
+$66.9K |
| 3 |
LPL Financial
San Diego,
California
|
+$19.4K |
| 4 |
JP Morgan Chase
New York
|
+$13.7K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$936K |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$769K |
| 3 |
DMK
David M. Knott
|
-$105K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$54K |
| 5 |
VF
Virtu Financial
New York
|
-$18K |
CORV Hedge Fund Activity: Q1 2018 in Review
25 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) for Q1 2018, worth a combined $38.3M — up 40% from $27.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CORV and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Stonepine Capital Management, adding an estimated $72.5K. The largest seller was Clough Capital Partners, cutting an estimated $936K.
- 25 institutional investors held Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) as of Q1 2018, down from 27 in Q4 2017.
- Funds reported $38.3M of Correvio Pharma Corp. Ordinary Shares (Canada) stock for Q1 2018, up 40% quarter-over-quarter.
- 3 funds opened new Correvio Pharma Corp. Ordinary Shares (Canada) positions in Q1 2018 and 5 closed out, a net change of -2 holders.
- The largest Correvio Pharma Corp. Ordinary Shares (Canada) buyer in Q1 2018 was Stonepine Capital Management, an estimated $72.5K added.
- The largest Correvio Pharma Corp. Ordinary Shares (Canada) seller in Q1 2018 was Clough Capital Partners, an estimated $936K sold.
Based on aggregated 13F filings for Q1 2018.